ReviewInnovation (Cambridge (Mass.))2026
Neuro-immune interactions in gastrointestinal oncology: Mechanisms, challenges, and therapeutic potential.
Review in Innovation (Cambridge (Mass.)), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neuron-tumor crosstalk in cancer: molecular mechanisms and translational advances.Molecular cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal (GI) cancers represent a leading cause of cancer-related mortality globally, characterized by a complex tumor microenvironment where bidirectional neuro-cancer-immune interactions critically influence disease progression. The CNS integrates ascending gut-derived signals and transmits descending regulatory responses through distinct autonomic neural pathways, while peripheral sensory, sympathetic, parasympathetic, and enteric neurons modulate innate and adaptive immune cell functions through specialized neurotransmitter circuits. This coordinated neural-immune crosstalk operates within the neuro-endocrine-immune axis, forming an integrated regulatory network that governs tissue homeostasis and tumor surveillance. Emerging evidence demonstrates that neural dysregulation promotes GI tumorigenesis through immunosuppressive mechanisms, while therapeutic neural interventions show promising efficacy in preclinical cancer models. The gut-brain axis represents a paradigmatic framework for understanding how neuroimmune signaling influences cancer progression and metastasis, revealing previously unrecognized diagnostic, prognostic, and therapeutic opportunities. Here, we review the molecular mechanisms underlying neuroimmune interactions in GI cancer pathogenesis and evaluate the therapeutic potential of neurally targeted interventions for cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.